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Abstract In this article on innovative medical treatment for serious conditions in Japan, we aim
to revise two widespread notions: first, that people living with severe conditions are all waiting for a
cure or are impatient to try out experimental treatment, in particular regenerative medicine.
Showing that motivations for cure seeking are complex and linked to somatic identity, we argue
that gaining a cure also means a new social normality, which for some people narrows the only
normality that is meaningful to them; and, second, that people living with a serious (latent)
condition necessarily define their lives as not normal in the light of normalisation. People with a
condition conceptualise normal life variously and multiply in the light of both individual and col-
lective experiences. The two revisions are crucial to attempts at understanding what makes people
seek experimental medicine. Comparing the narratives of people with four different conditions –
spinal cord injury, Duchenne muscular dystrophy, Diabetes Mellitus type 1 and cardiovascular
disease – it becomes clear that the difference between seeking treatment or not largely depends on
somatic identities; rather than through notions of (ab)normality, it is more adequately understood
in terms of the experience of somatic lacking and wholeness.
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Introduction
Regenerative medicine – among which various stem cell therapies – can be broadly defined as
a branch of translational research in tissue engineering and molecular biology. It deals with
the process of “replacing, engineering or regenerating human cells, tissues or organs to
restore or establish what is regarded as ‘normal function’” (Mason and Dunnill, 2008, p. 4).
According to Foucauldian theory the value of ‘health’ in modern, technologically advanced
societies is normalising, as it interconnects the qualification of individuals as ‘normal’ human
beings with the imperative of correction (Foucault, 2003) as well as with the principles of
discipline and biopower (Foucault, 1994, 2003). Our research nuances this stance by
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exploring why some people with a serious condition seek experimental stem cell and other
biomedical interventions, while others do not. Our findings indicate that the will to adjust
the self as part of the processes of normalisation and responsibilisation (Rose, 2007), though
important, is too easily presumed in the light of what we refer to as the ‘dominant normal’.
Debates on ‘normality’ among scholars of disability studies criticise the dominant views of
disability as ‘provisional’ and ‘problematic’ (Campbell, 2012). For, in a world that
‘normalises’ disability, a ‘cure’ is seen as the quintessential solution and rehabilitation and
education second best (Tichkasky and Michalko, 2012; Tremain, 2005). Some authors
speak of the ‘biotechnological illusion’, questioning the idea that biotech enhancement or
‘normalisation’ can take place without considerable efforts and sacrifice, and that
normalisation can fix ‘the problem’ (Winance et al, 2015). Others have criticised forms of
health governance that define individuals as autonomous subjects expected to make
‘responsible’ choices among a narrowed down range of options (Callon and Rabeharisao,
2004; Davis, 2002, p. 30; Ho, 2008). On the other hand, there are also patient and health
organisations that zealously engage in activities aimed at finding stem cell ‘cures’ and
‘treatment’ (Sleeboom-Faulkner et al, 2016) and many patients participate in website forums
on the internet (Song, 2017; Kim, 2012) in the hope to find innovative biomedical cures or
means to raise their quality of life.
Experimental intervention in the field of regenerative medicine is an interesting case, as
overall uncertainty exists about whether their application is safe and can lead, to ‘correction’
or ‘return to normal’. These issues prompt us, not just to consider a variety of conditions that
define the relation between disability and normalisation, but also to probe further into the
subjectivities of people who question dominant notions of ‘the normal’. The uncertainty
around experimental biomedical technologies has led to various debates, whereby some
encourage the swift development of the field of regenerative medicine and urge their
accelerated application to cure patients; others, however, have described this haste as
‘hyping’ in terms of the ‘politics of hope’ (Brown and Michael, 2004; Novas, 2006; Hyun,
2013; Petersen et al, 2017), arguing instead for a ‘responsible’ and ‘ethical’ approach based
on scientific evidence (Bianco and Sipp, 2014; McMahon and Thorsteinsdo´ttir, 2010;
Ogbogu et al, 2013). Although interviews have been held with patients seeking stem cell
treatment (Song, 2017; Patra and Sleeboom-Faulkner 2011; Sui and Sleeboom-Faulkner,
2015; Bharadwaj; Chen and Gottweis, 2013; Salter et al, 2015), the debates, however, have
not been based on the diversity of views among people with various diseases and disabilities.
In this study it will become clear that, rather than just one hegemonic view, various
discourses of normality reign and a wide spectrum of factors, conditions and motivations are
involved in the decision-making around experimental treatment. Patients express a great
diversity of reasons for undergoing regenerative medical interventions, varying from ‘last
resort’ and ‘improving the quality of life’ to following examples (‘others have done it’) and
calculation (‘I can afford it’; ‘I stand a good chance’), while motivations varied from spiritual
(hope, prayer, pilgrimage) and altruistic (I do it for my family; perhaps other patients can
benefit) (cf Song, 2010; Patra and Sleeboom-Faulkner 2011; Sui and Sleeboom-Faulkner,
2015; Bharadwaj, 2013; Sakai, 2014). Here, we try to deepen our understanding of decision-
making on seeking treatment by examining how aims are set and motivations are forged in
relation to people’s particular condition.
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Seeking innovative/experimental treatment
A variety of biomedical stem cell interventions have attracted the attention of patients. A
well-known type of stem cell is the embryonic stem cell, a so-called pluripotent stem cell,
which has the ability to develop into all cells of the body. However, as it involves the
destruction (or at least manipulation) of the embryo, it is controversial, and the use of the
embryo or foetus for the purpose of stem cell therapy is not allowed in Japan (Mikami and
Stephens, 2016; Sleeboom-Faulkner, 2008; Sleeboom-Faulkner et al, 2016). Currently,
another kind of pluripotent stem cell called induced pluripotent stem cells (iPS) is providing
hope to many patients in Japan. Human iPS cells were pioneered in 2007 by 2012 Nobel
laureate Shinya Yamanaka. In Japan iPS has raised many expectations both for its
extraordinary ability to generate embryo-like cells from adult tissues and for its indigenous
origin (CiRA, 2015). Government support and deregulation have accelerated the clinical
application of cell therapy, and in autumn 2014, a human clinical study using iPS was
initiated with patients suffering from age-related macular degeneration (AMD) (Kyoto
University News, 2016), followed by the announcement of an official list of other candidate
diseases to be treated using iPS (CiRA, 2015).
There are many other advanced biotech treatments under development, which are thought
to raise the hopes of patients and people with disabilities on a return to ‘normal’ life. For
instance, cell sheet engineering, which is currently under clinical experiment in Japan, has
raised the expectations of people with cardiovascular disease (Okano, 2012). But although
regenerative medicine is providing hope to patients, at the time of field research these
treatments were not yet firmly established or recognised internationally. Nevertheless, some
patients are longing for opportunities for clinical experiments at home even when risk is
involved. Others, however, prioritise safety and wait until treatment is established. Some
patients might travel abroad for controversial cell treatment, including embryonic stem cells,
while others do not. The question we explore in this article concerns the differences in this
decision-making. It is often presumed that whether persons with a disability try out
unrecognised stem cell interventions and travel abroad for controversial treatments depends
on the urgency of the diseases and the financial situation of patients (interview, journalists,
13 May 2014; Tamai and Kasuga, 2009, p. 16). However, our research indicates that
persons with seemingly urgent conditions are not necessarily more desperate for regenerative
medicine than those with less urgent conditions; and, the financially well-off are not
necessarily more enthusiastic about travelling abroad for new medicine than those who are
less well-off, even when formally recommended treatment is available.
The expectations individuals with disabilities have of regenerative medicine and their
desire to be cured are intimately related to their ‘knowledge’, perceptions and experiences of
their condition. Such perceptions and experiences are formed through both their somatic
experiences and the socio-cultural conditions of their history, and their institutional and
socio-cultural environment. We refer to this as their somatic identities, a notion related to
that of ‘somatic individuals’ (Novas and Rose, 2000) and ‘biological citizenship’ (Petryna,
2002; Rose, 2007). Whereas the concept of somatic individual refers to the new relations
between body and self, which have become possible through genomics and other
biotechnology, we place the concept of somatic identity in the context of somatic experience
and group identity. Here, we do not so much refer to the socio-political organisation of
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individuals that share a somatic identity, as is the case with the notion of ‘biological
citizenship’, but we use it as an analytical concept to understand the formal/informal
decision-making of individuals on the basis of their disease/disability experience. For
example, a person’s struggles with certain disease symptoms could differ depending on the
effects of pre-existing treatment. The availability of wheelchairs and other medical devices
and medical insurance influences the experience of disease. The life satisfaction of
individuals with a disability may also depend on employment opportunities and infrastruc-
tures for sports activities and relaxation. The history of the social perception of a disease
matters, too, for instance, when a disease has been intensely disliked in society and has been
a target of eugenics. The activities of health movements, such as campaigns against
stigmatisation, too, can influence the self-image of individuals with particular conditions.
Normality and the importance of somatic identity
In this article, we analyse narratives of persons with four different diseases regarding their
decision to seek innovative medical interventions. We have focused in particular on the
notions of ‘being cured’, ‘expectations of regenerative medicine’ and the actions undertaken
by them to ‘find a cure’, while taking into account the various socio-cultural meanings of
their diseases in the context of Japan. The four diseases in question include spinal cord injury
(SCI), diabetes mellitus type 1 (DM1), Duchenne muscular dystrophy (DMD) and cardio
vascular disease (CVD). From the outset, we expect that the different characters of these
diseases would shed light on factors important in seeking medical intervention. The
conditions differ in various respects: they can be genetically inherited (DMD, sometimes
DM1 and CVD) or acquired suddenly (SCI, DM1 and CVD), and lethal (CVD) or
progressive (DMD, DM1). Innovative and experimental treatments are available in the field
of regenerative medicine for all four diseases, but for some conditions there are other, more
or less established, treatment options, which allow a person with the condition to lead what
is regarded as an “almost ‘normal’ life” (DM1, CVD), while individuals with SCI an DMD
are generally presumed to look to medical innovation, including regenerative medicine, for
medical cures. As a matter of course, the perceptions and experiences of different diseases
vary, but during field research, we found that there are also differences among individuals
with ostensibly the same condition. By comparing individuals with different and similar
conditions, we aim to shed light on what brings individuals to participate in clinical trials
and travel abroad for experimental treatment.
According to Georges Canguilhem (1989) it is the experience of suffering, not normative
measurements, that shapes ill health. Ill health should not be confused with ‘abnormality’, as
disease conditions can be seen as part of ‘normal life’, and as a person with a disability can
lead a ‘normal’ life (Canguilhem, 1989, pp. 200–201). So what does lead some persons with
a disability to seek risky, unauthorised treatments to achieve ‘normality’ but not others. In
Foucault’s work, dominant medical norms establish what is normal in modern society. Thus,
persons with ‘disabled’ bodies do not fulfil social norms and are perceived as ‘unnatural’,
which makes it, for instance, hard for them to find employment. In societies that rule not
through violence, but through ‘free will’ and ‘norms’, normalisation is delegated to state and
non-state institutions, which engage in what Nikolas Rose calls the “responsibilisation” of
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the population in advanced liberal democracies. It is not violence, sanctions or force that
underlie normalisation here, but political discourse and individual choice linked to
responsibility, free will and civil rights (Rose, 2007). In such democracies, individuals are
expected to take responsibility for their health through free choice between option that
public discourses define as ethical (Callon and Rabeharisoa, 2004).
Normalisation and responsibilisation play an important role in the lives of people with a
disability. In democratic societies facilities exist that allow them to find a niche as a ‘normal’
individual with a disability. However, when it comes to options outside frameworks that
define the norm, such as refraining from recommended ‘normal’ treatment or opting for
risky and experimental medical treatment, our research suggests that somatic identity – the
social experience and awareness of somatic lacking/wholeness - is crucial. To better
understand this kind of decision-making, we need to gain insight into the experience of
‘lacking’ among persons with a disability when confronted with experimental treatment
options.
Method
Between April and July 2014, Masae Kato interviewed fourteen individuals with chronic
SCI, eight with DM1, three with CVD and eleven with DMD. Margaret Sleeboom-Faulkner
interviewed four members of the Japan Spinal Cord Foundation (JSCF hereafter) and one
individual with DM1. All interviews were semi-structured and lasted between 1 and 2 h. In
conducting the field research, we first approached leaders of organisations for SCI, DMD
and DM1, which connect various patient networks in the country. Organisations of SCI and
DM1 were relatively accessible compared to those of other diseases, in that members of both
are active in updating their websites, hold regular meetings and have a contact person. In
general, leaders of the visited health organisations are aware of available medical treatments,
both nationally and internationally, including methods of rehabilitation and regenerative
medicine. To the best of our knowledge, there is no organisation for individuals with CVD in
Japan. We were introduced to individual patients with CVD by medical specialists. The
organisation for DMD is led mainly by parents of individuals with DMD, but we spoke with
the latter directly. The snow-ball method generated further contacts. Interview questions
related to a wide range of topics, including needs, financial conditions, local government
support, their views on regenerative medicine, the current treatment they currently undergo
and how they have been getting along with their condition.
We also interviewed over a dozen medical doctors specialised in these four conditions. The
specialists provided an overview of the state of the art in the area of treatment and explained
guidelines regarding regenerative medicine. We further spoke with over thirty scholars in the
fields of biology, ethics and public policy to learn about health movements in Japan, as well
as about their views on policies regarding regenerative medicine. Finally, we interviewed
informants from various other backgrounds, including journalists specialised in stem cell
‘tourism’ (Song, 2010). We also attended symposiums and meetings related to these diseases
and to regenerative medicine, and went to health-group meetings that discussed group
activities, new therapies and administrative and financial matters.
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It is beyond the scope of this paper to make a full comparison between the ways in which
the symptoms of the four diseases are experienced in Japan, but we have tried to provide a
brief overview of the available infrastructures, facilities, socio-cultural environment and
nature of the conditions to shed some light on the contexts in which persons with a disability
or condition make decisions about seeking innovative and experimental treatment.
Although the number of interviews with persons with the four diseases is not
representative of populations of individuals with the four conditions in Japan, in-depth
interviews with them are intended to generate insight into the relation between seeking
experimental and innovative treatment, and self-perception, identity and notions of
normality. As far as we know, no other research has compared the pursuit of experimental
treatment from the points of view of individuals with different conditions. We hope, first, to
contribute new insights into the variety of needs of people with four different conditions,
including the search for cures; second, to shed further light on the notion of normality on the
basis of these insights and third, call attention to the role of somatic identity, which we
define as the social experience and awareness of somatic lacking/wholeness – in the daily-life
experience of persons with a disability.
Next we discuss the views on experimental treatment of persons with the four conditions,
after which we summarise our findings in relation to normalisation in the conclusion. We
adjusted our use of the notion of ‘patient’ to the way in which our interviewees felt about
themselves. This means that we used the word ‘patient’ when referring to those who
identified with the idea of ‘receiving medical treatment’ as essential to their life; in situations
where receiving medical ‘treatment’ was not relevant, we refer to ‘individuals or persons
with a condition’. Using a similar principle, we either refer to ‘patient organisation’ or
‘health organisation’. The names of interviewees cited in this article are all pseudonyms.
Four conditions
Persons with the four conditions forge different views of normality and experience it
differently. We argue that although normalisation figures importantly in the lives of many
individuals with the four conditions, somatic identity is crucial to the extent to which
patients seek treatment, and define their sense of normality.
Spinal cord injury
This section on SCI illustrates how interviewees with SCI imagine themselves as somatically
lacking vis-a-vis dominant norms in society. Acceptance of the self as having a disability is
problematic. This is expressed in the importance of and motivation to get back what is lost.
All the SCI interviewees are chronically disabled, with an average of 12 years, the longest
40, and the shortest 1 year. SCI is officially defined as a disability (障害) in Japan, meaning
that local governments supply a pension for them (障害者年金) and their carer. The amount
of pension and the number of hours of daily care depend on the severity of the disability, as
well as the regulation of local governments. On average interviewees received some €800 per
month, which many consider as insufficient. Some have jobs at a disabled people’s office,
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which tops earnings with some hundred euros a month. When injured at work, individuals
with SCI are eligible for industrial accident insurance (労働災害保険). They can claim
expenses for a disability-adjusted car; disability aids, such as wheelchairs, are paid by the
government. Medical expenses are discounted both for individuals with a disability and
family members.
When the Center for iPS Cell Research and Application (CiRA) was opened by Professor
Yamanaka’s research group in 2007 at Kyoto University, SCI and DM1 were on their
agenda as treatment targets. The aim was to move from basic research to clinical application
within 10 years. Currently, CiRA is building a cell bank with a stock of various types of iPS
cells for application to individuals with SCI within 6 months of injury – to prevent chronic
damage. In June 2014, a team led by Okano Hideyuki at Keio University started a clinical
trial to examine whether initiating treatment soon after SCI can help to ease paralysis and
other conditions (The Japan Times, 2014). Okano’s team is leading research on regenerative
medicine to treat SCI, supported by the JSCF. In June 2014, JSCF donated 5 million yen
(€37,000) to CiRA to support iPS research (interview, leaders of JSCF, April 2014). So far,
main treatment options for SCI patients are rehabilitation, massage and physiotherapy to
improve physical functions.
Among the individuals interviewed, those with SCI expressed the greatest expectation of
innovative treatment in the field of regenerative medicine, but they were careful in the way
they expressed hope, as they know that, once chronic, spinal cord damage is hard to cure,
and forthcoming clinical applications only enrol patients within 6 months after injury.
Nevertheless, a 2014 symposium of the JSCF was entitled “Walk again: Challenges for
Chronic Patients”, indicating high hopes for a cure. As many people with SCI engage in
sports before their injury and often become disabled early in life, the inability to engage in
some physical activities was poignant, often mentioned in the context of the wish to ski in
the mountains or play rugby again. Interviewees said that SCI “took the joy out of my life”
(interview, 22 April 2014), “totally damaged my life overnight” (interview, 27 April 2014)
and “is the greatest regret in my life” (interview, 9 May 2014). Patients’ expectations of
regenerative medicine should be understood in this context. Patients say, “even if iPS cells
would turn into cancer cells, I would still try it. Cancer is more acceptable than not being
able to walk” (interview, 9 May 2014) and “if I could ever walk again I would not mind
dying” (interview, 22 April 2014). For SCI patients, regenerative medicine, especially iPS
research, is what “might give life once again” (interview, 27 May 2014) and what “might
enable the world where SCI patients do not exist any longer” (interview, 9 May 2014).
Single patients under the age of 39 (5/14) said that marriage and having children were their
dreams, and these dreams were narrated as part of their expectations from regenerative
medicine. Ms Sato said,
A generation ago, SCI patients were infertile because of paralysis. But nowadays it has
become possible for some SCI patients to have children with the help of infertility
treatment. But it cannot help me yet… Among patients, there is an atmosphere that
those who are married and have children are the winners. …I hope that regenerative
medicine can solve this problem.
Between 2003 and 2007, among individuals with the four conditions, only those with SCI
engaged in stem cell tourism to China. The treatment used Olfactory Ensheathing Glia cells,
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or OEGC, obtained from the brains of aborted foetuses. Although the treatment was
generally controversial among scientists and in the mass media (NHK, 2005; Sakagami,
2013; Tamai and Kasuga, 2009), thirteen SCI patients travelled there (interview, 22 April
2014). We interviewed two of them. Mr Saiki, who travelled there in 2005, said,
One cannot just wait. If you want to walk again, you must not just follow others. I
chose to undergo the treatment despite its negative reputation. (Interview, 9 May
2014)
Ms Sawa, who also went to China in 2005, said,
One must not have judgment about the treatment because it involves China. You have
to be open to change and innovation, if you want to fulfill your dream. (Interview, 27
May 2014)
Both spent approximately 3 million yen (some €25,000) for the whole trip, including
treatment. Neither was financially at a deadlock nor particularly well-off. Mr Sawa said that
he decided to travel for treatment because all the treatment costs, including rehabilitation
and wheelchairs, were covered by his labour insurance and the state health insurance,
though he would have paid for the treatment himself.
Currently, SCI patients expect more from iPS cells and no longer travel abroad, as hardly
any positive results were witnessed from OEG cells interventions. Among our interviewees,
those with SCI and their partners were the most willing to try unestablished scientific
interventions. Ms Sagami, whose husband sustained SCI a year ago, says,
I regularly participate in JSCF’s meetings, because I do not want my husband to miss
any chance to participate in clinical trials. If there is a chance, and even though the
therapy is scientifically not fully established, I will be the first go. (Interview, 25 April
2014)
During field research, individuals with SCI and DMD showed remarkable contrast in their
attitude towards disability and the wish to be cured. Individuals with both conditions are
confined to a wheelchair, but those with DMD were born with their condition, while those
with SCI acquired the condition suddenly. Those with SCI clearly showed more reluctance to
accept their disability. Individuals with SCI reported that for many years after the injury they
were depressed, became violent, did not go out of the house at all, avoided seeing their body
in mirrors or meeting friends they had known before injury. Although many individuals with
SCI have established a balance in their lives, and have found a way to get along with their
disability, a common narrative among them was, ‘I wish I could walk again before I die’.
While it is possible for persons with SCI to imagine walking, because they know what it is, as
we discuss below, it is an unreal notion for most individuals with DMD.
Individuals with SCI are aware that their condition is difficult to treat once it becomes
chronic, and that, if there is any treatment possible at all, it will not be in the near future. So
almost all the persons with SCI we interviewed – even those who travelled to China –
indicated that while they expect some positive developments from regenerative medicine,
they do not want to become obsessed by the idea of being cured, and would rather enjoy life
as it is for now. For instance, our interviewees with SCI engaged in sports activities, travelled
both within Japan and abroad and invested time into making new friends.
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The narratives of interviewees with SCI are of people that want to return to ‘normal’ life,
life without limitations. They regard themselves as severely limited, which is especially
poignant as their life expectation and mental ability are usually regarded as ‘normal’. Of
course ‘normal’ here is the dominant mean – and therefore does not mean without
limitations. Scientists receive much support from the SCI association to find a ‘cure’, and to
help them to return to ‘normal life’. As many persons with SCI are not patients (in need of
regular treatment by a medical professional), ‘being a patient’ denotes receiving treatment,
which implies a possibility of getting better. The dreams and activities of our interviewees
with SCI belong to a previous life, often cut off in bloom: remembering what it is to walk
makes it hard to accept a different bodily self, both physically and mentally; not having a
choice causes a sense of deprivation, rendering a sense of enjoying a full life impossible. Even
though jobs can be found and pensions are provided, somatic normality among people with
SCI experience a continuous sense of lacking. Those among our interviewees with SCI that
are prepared to take considerable risk often do so to regain their former life and its meaning.
Duchenne muscular dystrophy
Our interviewees with duchenne muscular dystrophy (DMD) are much less cure-oriented
than those with SCI. We illustrate how identity plays an important role in the experience of
normality. DMD may be regarded as a condition entailing many disabilities, but in
interviews, persons with DMD express a strong sense of self and their own normality,
regardless of what society and science may consider ‘normal’.
DMD is officially defined and referred to as an incurable disease (難病) in Japan. Similar
to individuals with SCI, those with DMD also receive a pension of approximately €800 per
month. While some individuals with SCI receive a labour pension if injured during working
hours, individuals with DMD usually have no employment history, and live on their pension
and parents’ financial support. The average age of our DMD interviewees is 21, and they live
with parents or in institutions for people with disabilities. Traditionally, their mothers take
care of them, but in 2005 the welfare system changed so that persons with DMD can secure
carers from local governments (see also Welfare and Medical Service Network System,
2016). Persons with DMD are usually allocated a relatively high number of hours of care, up
to 20 h a day.
So far, there is no cure for DMD, though machines and medicine can prolong lifespan,
including cough assistance machines, wheelchairs and cardiotonic drugs. In the field of
regenerative medicine, DMD research promises fundamental improvement or cures, albeit
not in the near future. Most recently, a study was published on gene therapy for DMD using
programmable nucleases to restore the dystrophin protein (Lin et al, 2014). Furthermore,
exon skipping, a form of gene therapy, is on clinical trial, aiming to lighten symptoms of
Duchenne to the level of that of Becker (Nippon shinyaku, 2013).
Having had symptoms at an early age, most of our interviewees with DMD expressed a
mild desire to be cured. More than half of them said walking was not a reality, and they
doubted that regenerative medicine would enable them to do so. DMD is a disease whereby
an individual progressively loses the ability to engage in activities over the course of life.
Many persons with DMD express frustration on this point and fear for the future. A young
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boy who loves playing the piano expressed how disappointing it was to confront the fact that
he could no longer play. For some time, he avoided having the piano in sight. Nevertheless,
we found that individuals with DMD dealt with their condition in a composed manner. Mr
Masaki said,
I have lost the ability to do one thing after another, and this is a fact. There is no
judgment about it. It is a fact. The symptom of DMD is a sequence of these facts, no
more and no less. DMD means aging comes early. (Interview, 16 May 2014)
Another person with DMD, Mr Momose, said,
I can imagine SCI patients would wish there had been no accident that caused the
injury. But in our case, we are born with this physical condition. It is myself. Although
I believe Yamanaka is a great scientist, I cannot imagine anything can change our
genetic condition. (Interview, 16 May 2014).
Many of our DMD informants expressed an obstinate reluctance to perceive their disability
in a negative manner. A person with DMD who runs his own non-profit organisation (NPO)
that aims to enhance a barrier-free life for sufferers said,
I feel content with my activities in the organisation, allowing me to improve social
conditions for disabled people. Without my disability, I am no longer myself. I lived
my life based on the fact that I have DMD. I would be at a loss and without a purpose
in life without DMD. … I think our genetic condition is a property of humankind
(jinrui no isan). I do not agree with any attempt to erase such genetic sequences.
(Interview, 11 May 2014)
This informant views his disability in a positive way, as being an integral part of his being.
Calmly dealing with the disease and obstinately resisting the idea to perceive DMD as
something to be removed or changed, this tone of argument reminds us of Japan’s disabled
people’s movement’s discourses against eugenics (Matsubara, 1998). Narratives of persons
with DMD on the idea of ‘being cured’ and their expectations from regenerative medicine
need to be understood in the context of eugenics in Japan.
The introduction of the National Eugenic Law dates back to 1940. In 1948, this law was
revised into the Eugenic Protection Law, a stricter form concerned with “preventing the
birth of inferior descendants” (Kato, 2009), articulating legal procedures to sterilise people
with genetic disorders. This was part of the government’s policy to re-build Japanese society
by enhancing the quality of the population after the devastation of the war. Some 16,000
people were sterilised between 1949 and 1994 in the name of ‘eugenic operation’ (Shim-bun,
1996). After amniocentesis was introduced into obstetric practices in the 1960s, the disabled
people’s movement started to keep an eye on policies and regulations of prenatal testing.
Although the Eugenic Protection Law was revised in 1996 and legal procedures for eugenic
operation are no longer in the law, reproductive genetic technologies remain high on the
agenda of the disabled people’s movement in Japan.
Since 2004, DMD is classified as a severe genetic disorder in Japan, and it has been a
target of pre-implantation genetic diagnosis (PGD). Individuals with DMD contend that if
Japan’s society for obstetricians (日本産科婦人科学会), an authority in the field, legitimises
the elimination of embryos with DMD before embryo transfer, it is an official denial of the
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value of life of people with DMD, or a practice of eugenics (Mizoguchi, 2001; Okamoto,
2001). The notion of our interviewees with DMD is to accept the disease as part of
themselves, rather than trying to get rid of it. This contrasts sharply with the perspectives of
people with SCI regarding their disability and the determination of ‘finding a cure’.
As a genetic disorder, DMD has not just biological but also socio-cultural implications for
reproduction. None of our interviewees had partners, were married or had children. Nor did
persons with DMD regard reproduction as realistic. This is not difficult to imagine, as they
are usually young, and have had symptoms since childhood. But these factors are augmented
by the fact that discrimination against genetic disorders exists in Japan. Marriage is usually
an issue of bringing together two family lines rather than two individuals, and if a genetic
disorder is introduced to the mixture through one family line, the other regards it as a
contamination of theirs (Kato and Sleeboom-Faulkner, 2009). Related to this, the birth rate
of individuals with DMD is decreasing in Japan (Kondo, 2016), which has been made
possible through knowledge of genetic inheritance – after genetic counselling, female carriers
tend to terminate pregnancy (Kato and Sleeboom-Faulkner, 2009; Kondo, 2016).
The physical conditions and needs of people with DMD are particular to this group and
involve a more conservative attitude towards what is possible in the present. People with
DMD often struggle with physical exhaustion in everyday life. This contrasts with people
with SCI, who generally do not suffer from chronic exhaustion. Furthermore, engagement in
support for the development of innovative medicine does not gain momentum due to the
young age and often dependent lifestyle of persons with DMD. Additionally, the causes for
and types of muscular dystrophy differ greatly, so that collective prioritisation of certain
types of innovation is difficult (interview Medical Doctor specialised in DMD 24 April
2014). Regarding travelling abroad, most persons with DMD said that travel by airplane,
even for a vacation, is complicated and exhausting because of their physical condition: it
requires carers for many hours a day, a wheelchair and machines such as lifts. This contrasts
with individuals with SCI, who are also dependent on a wheelchair, but travel abroad on
vacation to do sports and for controversial treatments. Meetings of the DMD organisation
do not focus much on political lobbying with pharmaceutical companies, but tend to be
informal meetings for discussing how to improve the everyday needs of people with DMD.
Nevertheless, interest in new medicine is not entirely non-existent among persons with
DMD. There is interest in treatment that can stop progress of the condition or alleviate
symptoms. And although our interviewees tried to minimise medicine, all were aware that
survival depends on it. The DMD organisation takes great interest in new medical
developments, but follows its possibilities with a critical eye rather than with great
expectations and hope.
Most DMD persons are also patients, in the sense of being under medical treatment. But,
compared to people with SCI, they seem to accept their condition, and do not necessarily
always regard themselves as patients. Interviewee narratives and discussion on the value of
human life in Japan indicate that people with DMD have developed their own sense of
normality next to an awareness of dominant notions of normality. Despite somatic
limitations and a limited life span, persons with DMD have developed a somatic identity that
cannot but accept DMD as the norm. Although (and perhaps because) genetic discrimination
in Japan discourages reproduction in people with genetic disorders, Japan also has a strong
activist culture against genetic discrimination, which is reflected in the IVF and PGD
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regulation that prohibits selection on the basis of disease (Kato, 2009). Nevertheless, most
persons with DMD and the DMD health movement are interested in facilities that can
support their daily lives rather than in a ‘cure’. Due to their dependence on carers, persons
with DMD often regard themselves both as patient and as disabled, but they also regard
themselves as whole persons important to human kind. In fact, some interviewees pointed
out that being disabled emphasises their humanity.
Type 1 diabetes
Compared to SCI and DMD, in Japan DM1 is regarded as a disease (疾患) rather than as a
disability: as long as those with DM1 inject insulin with discipline, they do not appear to be
different from any other healthy person, and they seem to lead a ‘normal’ life. For this
reason, unlike individuals with SCI and DMD, those with DM1 do not narrate their disease
in terms of being targeted by eugenics or suffering from social barriers. The narratives of our
interviewees show how a somatic condition that allows ‘normality’ through discipline keeps
them from experimenting with new medical interventions.
Parents of individuals with DM1 of under-twenty years of age do not have to pay a
premium for health insurance to receive medical care. Patients with DM1 of 20 years and
above pay a national insurance fee (€400 per year), and are reimbursed for 70% of their
medical expenditure, just as is the case with ‘healthy’ Japanese citizens. A health check and
insulin cost around €250 per month. However, at times of severe economic recession and
high unemployment, some cannot afford to pay the national insurance tax. A person with
DM1, active in the Insulin Dependent Diabetes Mellitus (IDDM) network, said that some 30
per cent of network members are not undergoing monthly health checks and do not receive
insulin injections. It is a serious social problem that citizens cannot pay for insurance and
cannot afford to see the doctor. Many persons with DM1, according to this person, fear
kidney malfunction and becoming blind (interview, 24 May 2014). For individuals with the
disease, there are no specific public services, no special pension plans, subsidies or carers. But
if the condition is accompanied by complications, such as blindness or kidney failure,
individuals with DM1 receive a pension for people with disabilities.
Unlike type 2 diabetes individuals, DM1 does not require following a strict diet, and
taking insulin is the only treatment option because the body does not produce it. The disease
often appears at a relatively young age (juvenile diabetes). The average age at the appearance
of symptoms in our informants is 9, but onset is usually earlier. Children with DM1 and
their parents all said that they were shocked to hear that they would have to inject insulin for
the rest of their lives. For children, mothers are usually the main carers and some of them
visit schools two to four times a day, to inject insulin and to measure the blood sugar. Two
interviewees said that they had considered committing suicide when they were first
diagnosed.
Having the disease restricts the lives of individuals with DM1 especially in two areas:
reproduction and employment. Among our fourteen interviewees, seven started to have
symptoms before the age of reproduction, while two said they gave up the idea of having
children because of the disease. They were afraid their physical condition would deteriorate.
Male interviewees were more optimistic about reproduction: three of them, all childless,
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wanted to get married and have children; two were not sure (one woman and one man).
Among our fourteen interviewees, six were employed, three were housewives, three were
looking for a job and two were students. Among those who work, two own a business,
because of the discrimination they thought they would encounter during job-hunting; all
individuals with DM1 said that they are avoided by companies. Companies fear they will
have accidents and die on the job (interview, leader of a health organisation, 10 May 2016).
About this point, a father of a child with diabetes aged 13 said, “their survival is actually a
great proof of their trustworthiness. It requires discipline, punctuality, precision, and skill.
Therefore, it is not right that companies avoid hiring them” (interview 28 May 2014).
So far, insulin injection and islet transplantation have been the only means to live with
DM1. But in recent years, a number of studies have been conducted in the field of
regenerative medicine, including regenerating the pancreas, islets of Langerhans (pancreatic
cells which produce insulin) and pancreatic beta cells using iPS cells (Shanti, 2013; Japan
IDDM Network, 2016). DM1 is high on the list of Yamanaka’s research team and the
IDDM network aims for a ‘fundamental cure’ (根治 konchi) by 2025. For this, the network
actively collects money and annually donates funds to researchers. To gain access to the
fund, scientists have to formally submit a research proposal to the IDDM network, reviewed
by a scientific committee internal to the network. Every year, three research projects are
funded awards of €20,000 to €30,000, and they organise an annual scientific symposium for
individuals with DM1, inviting scientists who present their research on DM1 and
regenerative medicine (Interview, leader of a patient organisation, 10 May 2014; Japan
IDDM Network, 2014, 2016). The leader of the group, a father of a child with DM1, is a
scientist himself, which helps the organisation not only to approach scientists in the field of
regenerative medicine and disseminate information on regenerative medicine, but also to
organise scientific activities in a professional way.
Since DM1 was on the agenda of CiRA, ten patients expressed the wish to wait for
treatment to become available in Japan. Unlike DMD, but similar to SCI, persons with DM1
are actively in favour of treatment, and express the desire to, some day, no longer have the
need to inject insulin. Unlike the interviewees with SCI, however, seven out of the ten said
they did not want to take the risk of undergoing a clinical trial, not even in Japan. Reasons
they gave for this were: “as long as I accurately inject insulin, 90% of my life is the same as
that of others” (interview, 28 May 2015), and “DM1 is not drastically lethal, unlike cancer”
(interview, 16 May 2015). One individual with DM1 also said that, even when regenerative
medicine is scientifically established in Japan, he would wait at least 1 year before deciding
whether to try it (interview, 28 May 2015). Only one individual with DM1 said she might
want to try a clinical trial if it fits her condition (interview, 10 May 2015). Three individuals
with DM1 said that travelling abroad with the aim of undergoing experimental treatment is
troublesome, due to the need to carry insulin, and the time difference, which complicates the
regime of injecting insulin.
While for SCI patients regenerative medicine might be the only means to return to
‘normality’, for persons with DM1 regenerative medicine would not be essential to their
health, because following a medical regime enables them to lead a ‘normal’ life. Although
interviewees with DM1, unlike individuals with SCI, tended to have high expectations from
regenerative medicine, they would wait until the treatment is well established before seeking
it.
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Thus, Mr Date (52), a successful businessman with DM1 says that he is interested in
regenerative medicine, but will not participate in a clinical trial, not even if held in Japan.
Having been a patient for over 30 years, Mr Date trusts his doctor who, he says, saved his
life. Even if his medical treatment is not state of the art, and even if he dies from a medical
error, he would have no regrets. Mr Date trusts and follows his doctor’s advice. In his view,
the existing medical standard of treatment for individuals with DM1 in Japan, even without
regenerative medicine, is of the world top level. He believes this because he witnessed foreign
patients from the Middle East visiting his doctor, and he saw medical trainees from abroad
at his hospital. Even though he expects regenerative medicine to yield results soon, he is
convinced that he is already enjoying high-quality medical care, and sees no reason to try
experimental medicine, let alone to travel abroad.
Another reason for individuals with DM1 hesitate to participate in clinical trials is that
they worry that DM1 might reemerge because the medical intervention uses the patients’
own cells. Although individuals with DM1 expect regenerative medicine to enable life
without insulin, they do not want to take the risk; they prefer to wait until the medicine is
established. This contrasts with the narratives of individuals with SCI, for instance, who
show greater preparedness to take high risk.
The somatic identity of persons with DM1 is shaped by great uncertainty. This potentially
very serious condition develops at a relatively young age, but a ‘normal’ life is possible if
adhering to a medical regime in a disciplined manner. The latent possibility of developing a
severe condition makes developing a ‘normal’ social life – in the dominant normal sense –
very difficult, bringing some to consider suicide. This leads us to argue that to Canguilhem’s
negative definition of health as an absence of disease (Canguilhem, 1989) we should add the
absence of latent conditions, as they affect a healthy social life, including employment,
partner choice and self-definition. The conflicting possibilities that individuals with DM1
live with influence their decision whether to seek experimental treatment. Health
organisations for DM1 support scientific research into innovative therapies, but not all
individuals with DM1 are interested in participating in a clinical trial, being confident that
they can get by with a strict intake of medication. Those among our interviewees who are
interested prefer to stay in Japan, as travelling can be complex, and tend to want to go ahead
only when the therapy has been proven safe and efficacious.
Cardiovascular disease
The somatic identity of the three persons with CVD interviewed was influenced by their
experience of the phase of life they were in. Important is how they felt that their life so far
related to the ‘normal’ life cycle, including having a family, employment and their physical
condition. All felt that their condition had led them to be at odds with ‘normal life’.
Although they generally welcomed a cure for their condition, the reactions to this possibility
depended largely on the factors mentioned above.
Many of the problems associated with cardiovascular disease are related to the process of
atherosclerosis. Atherosclerosis is a condition that develops when plaque builds up in the
walls of the arteries. This build-up narrows the arteries, making it harder for blood to
circulate. If a blood clot forms, it can stop blood flow and cause a heart attack or stroke.
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According to the National Cerebral and Cardiovascular Center, a heart attack leads to death
in 20 percent of cases, and most sufferers die within 1 hour of the attack (Yasuda, 2012).
However, although survivors may have a good chance to return to ‘normal’, most require
medication, diet and an exercise regime. Some patients remain in a weak condition and may
require an artificial heart (人工心臓). Similar to DM1, as long as individuals with a heart
condition are disciplined in their lifestyle and observe a suitable medical regime, they do not
appear to be different from other healthy persons. A problem is, however, that individuals
with a heart condition do not always notice the progress of the disease.
In Japan, individuals with a heart condition generally do not receive a special pension or
care from the government, although some particular forms of CVD, such as cardiomyopa-
thy, are officially defined as a disability in Japan, meaning that persons with CVD receive a
pension. When annual medical costs are excessive in comparison to annual income, under
certain conditions, part of the costs are reimbursed by the local government through
“catastrophic medical expense coverage” (高度医療費制度).
A new treatment of regenerative medicine for myocardial infarction, which uses cell sheet
engineering, has been applied clinically to regenerate heart muscle. It was developed at the
Institute of Advanced BioMedical Engineering and Science Tokyo Women’s Medical
University together with Osaka University. The heart sheet technology has been condition-
ally approved as clinical treatment (Okano, 2012), but at the time of fieldwork it was still
undergoing clinical trial (Sakai and Okano, 2013; Leibing et al, 2016). Individuals with a
serious heart condition could be enrolled in clinical trials using cell sheets if no other
treatment was available. Treatment costs for the clinical trials were covered by the
University Hospital and the Ministry of Health, Labour and Welfare, but patients had to pay
for periodic check-ups before and after the operation, as well as the necessary medicines.
Among our interviewees, two males with cardiomyopathy participated in clinical trials, and
one, who had suffered a stroke, decided not to, although he had been offered this option. All
three were in critical condition after their heart attack.
Factors considered in their decision to participate in the clinical trial were employment,
family, phase of life and physical condition. Mr Chiba (36) and Mr Chino (53) said they
participated because they wanted to remain employed, alleviate the symptoms of the disease
and prolong their life span. Right before the operation took place, both were critically ill and
did not expect to live more than 1 year. At the time of interview, Mr Chiba had returned to
work for two months, while Mr Chino was still looking for a job. Finding employment, he
felt, was hampered by employers’ fears that they might cause an accident during working
hours. Mr Chino is no longer considered young and is not desirable in the job market. For
Mr Chiba, the phase of life he was in partly motivated his decision to participate in the trial,
as he wished to start a family. Mr Chino, however, was motivated by the opposite situation
of not having family members. He said, “I was not afraid of the trial because if it fails, no
one will be left behind” (interview, 11 June 2014).
Mr Chikuda (62), who had had a stroke in the previous year, chose not to participate in
the clinical trial. Although he recovered miraculously, Mr Chikuda was applying for early
retirement. He said,
The process of the trial would be too much for me, I thought. The stress would be bad
for my heart….My two children are grown up, and I have worked all my life. Now I
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feel it is reasonable …My priority is to maintain my life… I cannot move around like I
could before, but I accept it. (Interview, 11 June 2014)
The factors important to the decisions of Mr Chiba and Mr Chino – employment, family and
phase of life – also underpin the decision of Mr Chikuda: he believes that he has worked
enough, his children are grown up and he feels that he should not have to push himself any
more. Their decisions were not taken under pressure of a patient or health group, as none of
the three belonged to one: Mr Chiba said that he did not like to talk openly about his disease,
not even with others with a heart condition; Mr Chino said it would be depressing to discuss
physical conditions with others and Mr Chikuda said that even managing daily life is
exhausting, let alone participating in a patient or health group. All said that they had
received information on the clinical trial from their medical doctor during a periodical
check-up. The three persons with CVD gave the impression of feeling tired and being in need
of rest due to their physical conditions, and perhaps also because CVD was acquired at a
relatively advanced age.
Persons with CVD prefer to undergo treatment in Japan. None had considered travelling
abroad for treatment. According to one medical doctor, most individuals with a heart
condition are in their fifties or over when they have their first heart attack, and it is more
appealing to them to control their diet and do exercise than to travel abroad. Travelling,
being wearisome, is considered as part of the costs and difficulties of seeking treatment.
Actually, three interviewees said that even collecting information about treatment within
Japan is energy consuming, and they would rather depend only on their own medical
doctors. In addition, individuals with CVD expressed the view that the treatment cannot
bring back the life they led before the heart attack, and that any clinical trial would only
stabilise or ameliorate their condition to some extent.
Our interviewees with CVD were not caught up in the hype of medical tourism. For the
two with a bleak prognosis, it was important to find treatment, but they had not considered
going abroad. They just took the opportunity of participating in the heart sheet clinical trial,
which they had heard about through their cardiology doctors. They trusted information, had
no need to become a member of a patient or health organisation; their physical condition
made travelling difficult for them anyway. The one who chose not to participate in the
clinical trial planned to retire, even though he had recovered substantially, indicating that he
felt that he had worked long enough. Although full recovery was not expected, one of the
men hoped to later have a full reproductive life.
Conclusion
Most studies on the socio-economic factors relevant to why people participate in
experimental treatment in regenerative medicine focus on individuals that have decided to
undertake treatment, missing the opportunity to compare them with those who decide
against. They also have not made a systematic link between decision-making and the socio-
economic conditions of individuals with different disabilities and disease conditions. This
article, however, has explored the relation between four medical conditions and the search
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for experimental treatment and notions of normality in Japan, focusing on somatic identities
of individuals in daily-life experience.
Although we do not claim that our interviewees represent all people with SCI, DMD,
DM1 and CVD in Japan, the differences and similarities of narratives around normality
suggest that decisions to seek experimental treatment depend not so much on dominant
notions of normality, as on the experience of somatic lacking/wholeness, which we argued is
rooted in a person’s somatic identity and its embedding. The narratives of interviewees
indicate that the history of the somatic self is fundamental to the formation of the social
identity of individuals with different disease conditions: narratives indicate that persons with
SCI, whose former, often, active and relatively young life had been interrupted, tend to feel
incomplete and compare themselves to the dominant notion of normality; the narratives of
persons with DMD, who indicated that they are aware of their limitations compared to
other humans, do not imply that these limitations cause them to diminish their sense of
normality and worth as part of humankind; the narratives of persons with DM1, who find
out at an early age that their lives depend on a strict medical regime, show how they contend
with latent problems and uncertainties in relation to dominant notions of normality, while
the narratives of those with CVD indicate that they value themselves in the light of the
‘normal’ life cycle (Table 1).
The narratives showed that various factors related to the ‘normalised’ life cycle play a role
in seeking experimental treatment among persons with a disability and their relations:
experiences of suffering, life expectancy, financial means and the availability of alternative
therapy options are of great importance.
It has been argued that ‘normalisation’ plays a major role as a driver to ‘self-correction’
among people with disabilities. Thus, the image of a ‘disability’ and genetic ‘diseases’ in
society, the source of and trust in information about experimental treatment (GPs, hospitals,
patient movements, agencies, websites) and dependence on normalised state authorities and
private institutions are all factors that to some extent play a role in the motivation to adjust
health conditions to the ‘dominant normal’. All in all, however, the narratives also indicate
that the robustness of the somatic identity of people with a disability is underestimated. We
saw that while interviewees with SCI were not subjected to ideas around eugenics, they were
prepared to undergo experimental treatment to ‘return’ to their pre-injury physical
condition. Interviewees with DMD, however, who are subjected to eugenic discourses, are
sensitive to ideas that deny their value as humans. It is not just because genetic disorders are
disliked in society that interviewees with DMD reject the idea of ‘self-correction’ as their
responsibility; it is the somatic experience that has stabilised their socio-political sense of
identity as a valuable self. In the case of interviewees with DM1, we saw that the ever-
present psycho-physical threat of disease when failing to observe the medical regime makes
for a precarious self-identity. Treatment is only worthwhile when the pathway to ‘normality’
is safe and sound. For our interviewees with CVD, however, experimental treatment was
worthwhile seeking in the context of criteria inherent to a ‘normal’ life cycle.
Our findings suggest the need for further research on notions of normality, responsibil-
isation and discipline and hyping. We found that Canguilhem’s negative definition of normal
health in terms of the absence of disease should be extended to include references to the
absence of latent disease conditions and the absence of high risk of developing a condition.
Such ‘normal health’ we referred to as dominant health. Although people with some
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conditions – especially those with SCI and DM1 among our interviewees – express the need
to conform to a ‘dominant normality’, others – such as those with DMD among our
interviewees – do not take the dominant normal into account, regarding DMD as one of
many conditions inherent to humanity. In addition, the concept of the ‘normal life cycle’ –
expressed especially among those with CVD, DM1 and SCI – is an important frame of
reference for the decision-making regarding medical intervention. Notions of ‘normal’ life
expectancy influence the decision-making of our interviewees, leading some to conclude that
they are missing out, had enough or need to catch up.
The existence of different experiences of dominant normality also requires a review of the
notions of responsibilisation and discipline. People with disease conditions may be expected
to look after themselves and make decisions along the lines of what are publically recognised
notions of normality and bioethics. Those whose identity is forged by such dominant
normality may feel inadequate, undervalued or alienated when unable to adopt these.
However, the narratives of individuals with four different conditions in Japan shows that in
many ways, it is the social experiences of a particular somatic history that is crucial to
whether individuals feel they need to self-define in terms of the dominant normality or of
other, often competing, normalities. Thus, we saw that our interviewees with DMD are
widely supported in their own sense of normality and have been successful in changing the
regulation on embryo selection in Japan. The failure to participate in ‘responsible’ decision-
making and self-discipline can have repercussions, but it some cases it can also lead to the
recognition of broader values and their normalisation, actually liberating individuals from
decision-making.
The availability of ‘high risk’ and the ‘hyping’ of innovative biomedical therapies also
needs to be considered in this context. In the accounts of interviewees, the decision of
whether to have experimental treatment depends on the somatic identity of people and their
notions of ‘a life worth living’. Although decisions are based on discourses of medical
possibilities, availability and affordability, our narratives show that it is the somatic
experiences and identities if individuals that impregnate these terms with meaning in the
context of their perspectives of what are normal lives, life cycles and life values.
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